Haihe Pharmaceuticals is proposed to IPO, there are 8 products in the research into the clinical stage!

Recently, the website of the China Securities Regulatory Commission disclosed a report on the counseling record of Shanghai Haihe Pharmaceutical Research and Development Co., Ltd. ("Hai and Drugs"), which is provided by Guotai Junan.
means that Haihe Pharmaceuticals has launched an initial public offering and plans to go public.
hai and drug official website information shows that it has established a c-MET, IDH1, PI3K alpha, ERK, EP4 and other popular targets of the product pipeline, of which 8 are in clinical research stage, 5 have been in the United States to obtain clinical trials implied license.
Screenshot Source: China Securities Regulatory Commission's official website Haihe Pharmaceuticals was established in 2011, focusing on the discovery, development and commercialization of innovative anti-tumor drugs, the company's chairman is Ding Jian academician, the CEO is Dr. Dong Ruiping.
since its inception, haihe drugs have been favored by many capitals.
February 2019, the company completed a $146.6 million capital investment led by Huagai Capital.
July, the company completed another 1.2 billion yuan B round of financing led by Huaping Investment.
the company's other investors include China Merchants International, Junlian Capital, PCCW Capital, Stone Pharmaceuticals Group, Boyuan Capital and United Ventures, according to a hai and pharmaceutical press release.
according to Haihe Pharmaceuticals, the company has established a rich product pipeline covering c-MET, IDH1, PI3K alpha, ERK, EP4, EZH and other popular targets.
eight of these clinical trials are in clinical research and five have been approved for clinical trials in the United States.
, several of the drugs were developed jointly by Haihe Pharmaceuticals and Shanghai Pharmaceuticals.
RMX3001: An oral preparation of yew alcohol developed by Daehwa Pharmaceuticals of Korea has been approved in Korea for the treatment of stomach cancer, and Haihe Pharmaceuticals received its interest in Chinese mainland, Hong Kong, Taiwan and Thailand in September 2017.
RMX3001 is currently conducting Phase 3 clinical trials on stomach and breast cancer in China.
: A three-target oral small molecule kinase inhibitor (FGFR1/2, VEGFR1-3, PDGFR α/β).
is currently conducting key Phase 2 clinical trials in several research centers in China, covering nasopharyngeal cancer, small cell lung cancer and other cancers.
same time, Haihe Pharmaceuticals is exploring the effects of a variety of drugs, including driteni and PD-1/PD-L1 antibodies.
valley methinib: a powerful, highly selective small molecule MET kinase inhibitor.
, the drug is currently in China, Japan, the United States to carry out a number of clinical trials.
Preliminary clinical results show that gumetinite has better human pharmacodynamic characteristics, including longer metabolic half-life, good through the blood-brain barrier, etc., to met-positive patients with advanced non-small cell lung cancer showed initial efficacy and good safety, tolerance.
HH2853: A new, efficient and specific EZH1/2 dual inhibitor.
EZH1 or EZH2 is a catalytic sub-base of the precipitated genetic regulatory factor PRC2 complex, and certain tumors and immune cells use EZH2 to promote tumor production and progression and inhibit the response of anti-tumor drugs.
the drug has been approved in clinical trials in China and the United States for the treatment of patients with recurring/resuscitable non-Hodgkin's lymphoma or advanced solid tumors.
H2301: A new, efficient, specific mutant isochic acid dehydrogenase 1 (IDH1) inhibitor, IDH1 mutation in bile tube cancer, cartilage sarcoma, cerebral glioma and acute myeloid leukemia (AML) and other tumors widely occurred.
HH2301 showed significant anti-tumor activity in multiple solid tumor xym transplant models (PDX models) from patients with IDH1 mutations.
May this year, the drug was approved clinically in the United States to treat IDH1 mutations in solid tumors including advanced bile tube cancer, cartilage sarcoma and glioma.
CYH33: A new, efficient and specific PI3K alpha inhibitor that inhibits cell proliferation in stage G1 by inhibiting pi3K-mediated signaling paths.
that CYH33 has good safety and preliminary clinical efficacy.
based on information from the China Drug Clinical Trial Registration and Information Disclosure Platform, the product is conducting a Phase 1a/1b study in China for patients with advanced solid tumors.
May this year, the drug was approved in the United States for clinical studies of advanced solid tumors.
H2710: A new highly efficient, specific out-of-cell regulation protein kinase (ERK) kinase inhibitor for small molecules.
ERK kinase is a key kinase in the MAPK signaling pathway, targeting ERK to treat a wide range of tumors caused by mutations in the MAPK signaling pathway.
China Drug Clinical Trial Registration and Information Disclosure Platform shows that the drug is in China, the United States to carry out an international multi-center Phase 1/2 clinical study to assess the safety of HH2710 in patients with advanced tumors, tolerance and pharmacodynamics.
hai and drug research and development pipeline (Photo source: sea and drug official website) In addition, sea and drug product pipeline also includes the proposed treatment of solid tumors of hemintekang (II generation magpie alkali compounds), COX-2 inhibitor RMX 1001, EP4 subject antagonist RMX1002, the new antibiotic RMX2001, STING activator (code-named "SOMCL-18-202") and many other products.
hope that Haihe's drug IPO will go well and, with the help of capital, bring innovative therapies to patients at an early time.
.